Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Wuhan Ktai Biotechnology Company Limited is currently prosecuting a portfolio in the Biotechnology & Pharmaceuticals technology area. The data shows 1 pending office action, which is being reviewed by 1 distinct examiner. This indicates that the company's current patent efforts are concentrated in a single area of the patent office, specifically within 1 distinct art unit.
SARAH ABDOALATIF ALSOMAIRY is the busiest examiner for the company, with 1 busiest examiner pending office action. Since the company has only 1 pending office action in total, this examiner is responsible for the entirety of the portfolio's active workload. The prosecution path for Wuhan Ktai Biotechnology Company Limited is currently defined by this single relationship.
Practitioners can benefit from this concentration by focusing their analysis on the specific examination style of SARAH ABDOALATIF ALSOMAIRY. With only 1 distinct art unit involved, there are no conflicting procedural requirements to manage. The strategy for the 1 pending office action can be precisely tailored to the standards of the Biotechnology & Pharmaceuticals sector as interpreted by this examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALSOMAIRY, SARAH ABDOALATIF | 1 | 57.4% | +30.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17955743 | Use Of Biomarker Or Biomarkers Combinations In Preparing A Diagnostic Reagent For Fulminant Myocarditis And A Drug For Fulminant Myocarditis | ALSOMAIRY, SARAH ABDOALATIF | 70d |
| Art Unit | Apps |
|---|---|
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17955743 | Use Of Biomarker Or Biomarkers Combinations In Preparing A Diagnostic Reagent For Fulminant Myocarditis And A Drug For Fulminant Myocarditis | ALSOMAIRY, SARAH ABDOALATIF | 1678 | §112 | Final Rejection | 70d | Pending | Sep 29, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialWuhan Ktai Biotechnology Company Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Sarah Abdoalatif Alsomairy has the most, with 1 of Wuhan Ktai Biotechnology Company Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
